At the 61st ASH Annual Meeting & Exposition, Agne Paner, Rush University Medical Center, discusses her presentation: Myeloma: Therapy, excluding Transplantation: New Approaches in the Treatment of Relapsed/Refractory Plasma Cell Dyscrasias.
1. What are the major unmet needs in the treatment of relapsed/refractory multiple myeloma? (0:05)
2. What were the findings of the HORIZON study? (0:28)
3. What progress has been made in identifying biomarkers of response to Melflufen plus Dexamethasone in relapsed/refractory multiple myeloma? (1:37)
4. What combination therapies are being investigated for relapsed/refractory multiple myeloma? (1:53)
5. How does this treatment differ from other treatment options? (2:42)
Agne Paner has received consulting honoraria for advisory board from Oncopeptides.
Filmed at the 61st ASH Annual Meeting & Exposition 2019, Orlando, FL, USA.
Share this Video
Related Videos In Haematological Malignancies
Stephen Ansell, ASCO 2022: ECHELON-1, brentuximab vedotin plus chemotherapy for classical Hodgkin lymphoma
The ECHELON-1 study compared the experimental brentuximab vedotin plus chemotherapy (A+AVD) to standard ABVD chemotherapy in patients with classical Hodgkin lymphoma. Dr Stephen Ansell (Mayo Clinic, Rochester, MN, USA) discusses the design and findings of the study as well as what was learned and how this will impact the treatment paradigm. The abstract entitled ‘First-line […]
Stephen Ansell, ASCO 2022: Challenges and unmet treatment needs in Hodgkin lymphoma
Hodgkin lymphoma is a challenging disease and a cure, with current therapy, is possible in some but not all patients. Dr Stephen Ansell (Mayo Clinic, Rochester, MN, USA) discusses these challenges and the unmet needs in the treatment of Hodgkin lymphoma. Dr Stephen Ansell presented an abstract entitled ‘First-line brentuximab vedotin plus chemotherapy to improve […]
Shaji Kumar, ASH 2021: Final Overall Survival Results from the BELLINI Study
Dr Shaji Kumar, one of our Editors-in-Chief for touchREVIEWS in Oncology & Haematology, discusses his presentation at the 63rd ASH Annual Meeting & Exposition on the final overall survival results from BELLINI, a phase III study of venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. Intro: 00:12-00:18 Questions 1. Could […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!